All posts of Dr. Jean-Samuel Boudreault

Post-ASH 2018: An Analysis of the CASTOR, POLLUX and MMY1001 Studies in Patients with Relapsed/Refractory Multiple Myeloma

Poster presentation by Dr. Saad Z. Usmani This poster presentation is a subgroup analysis of two important phase III studies (POLLUX and CASTOR) and one phase I study (MMY1001). The purpose of this analysis is to validate the efficacy of adding daratumumab to standard therapy in patients with relapsed/refractory multiple myeloma (RRMM). The subgroup of […]

Post-ASH 2018: Double Versus Single ASCT in Patients with Newly-Diagnosed Multiple Myeloma

Oral presentation by Dr. Michele Cavo There is still controversy regarding the role of tandem double autologous transplant (autoBMT) for eligible patients with de novo multiple myeloma. This study provides long-term follow-up of three phase III studies involving patients induced with bortezomib-based triplet therapy (VTD or PAD), followed by at least one autoBMT and consolidation […]

Autogreffe double vs simple chez les patients nouvellement diagnostiqués avec MM: Analyse de suivi à long-terme (10 ans) d’études randomisées de phase III

Présentation orale par le Dr Michele Cavo Il existe encore une controverse quant à place de la double autogreffe (autoGMO) en tandem pour les patients éligibles atteints de myélome multiple de novo. Cette présente étude effectue un suivi à long terme de 3 études de phase III, de patients induits par un triplet à base […]

Analyse des études CASTOR, POLLUX, et MMY1001 chez les patients atteints de myélome multiple récidivant / réfractaire

Présentation par affiche par le Dr Saad Z. Usmani Cette présentation par affiche est une analyse de sous-groupes de 2 études importantes de phase III (POLLUX et CASTOR), ainsi qu’une étude de phase I (MMY1001). Le but de cette analyse est de valider l’efficacité de l’ajout du daratumumab au traitement standard chez les patients atteints […]

Efficacy of Daratumumab with Lenalidomide plus Dexamethasone vs. Bortezomib plus Dexamethasone R/R Multiple Myeloma

Oral Presentation by: Dr. Katja C. Weisel This study confirmed the efficacy of two novel triplet regimens (daratumumab in combination with lenalidomide plus dexamethasone [DRd] and daratumumab in combination with bortezomib plus dexamethasone [DVd]) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. Daratumumab is a monoclonal antibody that has stimulated the […]

Impact of Denosumab vs. Zoledronic Acid on Renal Function in the Treatment of Myeloma Bone Disease

Oral presentation by: Dr. Noopur S. Raje Osteolytic bone disease and renal involvement are complications of multiple myeloma with a strong negative impact on patients. The latest International Myeloma Working Group (IMWG) recommendations (J Clin Oncol 2013) include the use of bisphosphonate in all patients with multiple myeloma necessitating treatment. Denosumab (DMB) is a novel […]

Perspective on Long-Term Updates of the Bright and StiL NHL1 Trials at ASCO 2017

Oral Presentations by: Dr. Ian Flinn and Dr. Mathias J. Rummel The long-term updates on BRIGHT and StiL NHL1 studies were presented at ASCO 2017. The BRIGHT trial (Abstract 7500) is a phase III non-inferiority study aimed at comparing first-line treatment with bendamustine plus rituximab (BR) vs. rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) […]

Thoughts on the Results of the GENUINE Phase III Study with Ublituximab and Ibrutinib

Oral presentation by: Dr. Jeff Porter Sharman Ibrutinib is approved by the U.S. FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) including those with deletion of 17p (del[17p]). Patients with CLL harbouring interruptions in TP53 or deletion of 11q (del[11q]) experience an inferior response to ibrutinib monotherapy compared to standard-risk patients (O’Brien […]